USA - NYSE:KVUE - US49177J1025 - Common Stock
The current stock price of KVUE is 15.08 USD. In the past month the price decreased by -7.71%. In the past year, price decreased by -33.66%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| UL | UNILEVER PLC-SPONSORED ADR | 23.84 | 153.76B | ||
| EL | ESTEE LAUDER COMPANIES-CL A | 66.97 | 36.20B | ||
| ELF | ELF BEAUTY INC | 39.68 | 7.16B | ||
| BRBR | BELLRING BRANDS INC | 14.7 | 4.02B | ||
| COTY | COTY INC-CL A | 18.64 | 3.58B | ||
| IPAR | INTERPARFUMS INC | 18.75 | 3.08B | ||
| ODD | ODDITY TECH LTD-CL A | 22.09 | 2.70B | ||
| EPC | EDGEWELL PERSONAL CARE CO | 7.57 | 907.83M | ||
| HLF | HERBALIFE LTD | 3.89 | 845.50M | ||
| YSG | YATSEN HOLDING LTD-ADR | N/A | 735.24M | ||
| OLPX | OLAPLEX HOLDINGS INC | 13.63 | 727.12M | ||
| NUS | NU SKIN ENTERPRISES INC - A | 9.04 | 541.53M |
Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. The company is headquartered in Summit, New Jersey and currently employs 22,000 full-time employees. The company went IPO on 2023-05-04. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
KENVUE INC
1 Kenvue Way
Summit NEW JERSEY US
Employees: 22000
Phone: 19088741200
Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. The company is headquartered in Summit, New Jersey and currently employs 22,000 full-time employees. The company went IPO on 2023-05-04. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
The current stock price of KVUE is 15.08 USD. The price increased by 0.53% in the last trading session.
KENVUE INC (KVUE) has a dividend yield of 5.53%. The yearly dividend amount is currently 0.81.
KVUE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
The next ex-dividend date for KENVUE INC (KVUE) is August 13, 2025.
The Revenue of KENVUE INC (KVUE) is expected to decline by -2.81% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
KENVUE INC (KVUE) currently has 22000 employees.
ChartMill assigns a fundamental rating of 4 / 10 to KVUE. KVUE has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months KVUE reported a non-GAAP Earnings per Share(EPS) of 1.07. The EPS decreased by -12.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.37% | ||
| ROA | 5.23% | ||
| ROE | 13.22% | ||
| Debt/Equity | 0.73 |
24 analysts have analysed KVUE and the average price target is 22.38 USD. This implies a price increase of 48.38% is expected in the next year compared to the current price of 15.08.
For the next year, analysts expect an EPS growth of -7.91% and a revenue growth -2.81% for KVUE